Bioventus Statistics
Total Valuation
Bioventus has a market cap or net worth of $441.28 million. The enterprise value is $777.97 million.
Important Dates
The next estimated earnings date is Tuesday, August 5, 2025, before market open.
| Earnings Date | Aug 5, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
Bioventus has 66.36 million shares outstanding. The number of shares has increased by 3.56% in one year.
| Current Share Class | 66.36M |
| Shares Outstanding | 66.36M |
| Shares Change (YoY) | +3.56% |
| Shares Change (QoQ) | +0.85% |
| Owned by Insiders (%) | 2.56% |
| Owned by Institutions (%) | 35.72% |
| Float | 34.34M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | 8.78 |
| PS Ratio | 0.76 |
| Forward PS | 0.75 |
| PB Ratio | 2.95 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | 18.16 |
| P/OCF Ratio | 17.07 |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
The stock's EV/EBITDA ratio is 13.23, with an EV/FCF ratio of 32.51.
| EV / Earnings | n/a |
| EV / Sales | 1.37 |
| EV / EBITDA | 13.23 |
| EV / EBIT | 19.65 |
| EV / FCF | 32.51 |
Financial Position
The company has a current ratio of 1.43, with a Debt / Equity ratio of 1.97.
| Current Ratio | 1.43 |
| Quick Ratio | 0.81 |
| Debt / Equity | 1.97 |
| Debt / EBITDA | 5.69 |
| Debt / FCF | 15.30 |
| Interest Coverage | 1.10 |
Financial Efficiency
Return on equity (ROE) is -20.24% and return on invested capital (ROIC) is 4.18%.
| Return on Equity (ROE) | -20.24% |
| Return on Assets (ROA) | 3.33% |
| Return on Invested Capital (ROIC) | 4.18% |
| Return on Capital Employed (ROCE) | 7.66% |
| Revenue Per Employee | $610,429 |
| Profits Per Employee | -$33,644 |
| Employee Count | 930 |
| Asset Turnover | 0.76 |
| Inventory Turnover | 1.93 |
Taxes
| Income Tax | -6.30M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -4.20% in the last 52 weeks. The beta is 0.84, so Bioventus's price volatility has been lower than the market average.
| Beta (5Y) | 0.84 |
| 52-Week Price Change | -4.20% |
| 50-Day Moving Average | 6.69 |
| 200-Day Moving Average | 9.54 |
| Relative Strength Index (RSI) | 44.76 |
| Average Volume (20 Days) | 458,538 |
Short Selling Information
The latest short interest is 1.63 million, so 2.46% of the outstanding shares have been sold short.
| Short Interest | 1.63M |
| Short Previous Month | 1.22M |
| Short % of Shares Out | 2.46% |
| Short % of Float | 4.76% |
| Short Ratio (days to cover) | 3.30 |
Income Statement
In the last 12 months, Bioventus had revenue of $567.70 million and -$31.29 million in losses. Loss per share was -$0.48.
| Revenue | 567.70M |
| Gross Profit | 382.90M |
| Operating Income | 39.59M |
| Pretax Income | -48.54M |
| Net Income | -31.29M |
| EBITDA | 58.81M |
| EBIT | 39.59M |
| Loss Per Share | -$0.48 |
Full Income StatementBalance Sheet
The company has $22.80 million in cash and $366.13 million in debt, giving a net cash position of -$343.32 million or -$5.17 per share.
| Cash & Cash Equivalents | 22.80M |
| Total Debt | 366.13M |
| Net Cash | -343.32M |
| Net Cash Per Share | -$5.17 |
| Equity (Book Value) | 185.48M |
| Book Value Per Share | 2.24 |
| Working Capital | 74.62M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was $25.47 million and capital expenditures -$1.54 million, giving a free cash flow of $23.93 million.
| Operating Cash Flow | 25.47M |
| Capital Expenditures | -1.54M |
| Free Cash Flow | 23.93M |
| FCF Per Share | $0.36 |
Full Cash Flow StatementMargins
Gross margin is 67.45%, with operating and profit margins of 6.97% and -5.51%.
| Gross Margin | 67.45% |
| Operating Margin | 6.97% |
| Pretax Margin | -8.29% |
| Profit Margin | -5.51% |
| EBITDA Margin | 10.36% |
| EBIT Margin | 6.97% |
| FCF Margin | 4.21% |
Dividends & Yields
Bioventus does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -3.56% |
| Shareholder Yield | -3.56% |
| Earnings Yield | -7.20% |
| FCF Yield | 5.51% |
Analyst Forecast
The average price target for Bioventus is $14.40, which is 116.54% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $14.40 |
| Price Target Difference | 116.54% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 5 |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Bioventus has an Altman Z-Score of 1.1 and a Piotroski F-Score of 6. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 1.1 |
| Piotroski F-Score | 6 |
